Navigation Links
'New' human adenovirus may not make for good vaccines, after all
Date:8/11/2010

In recent years, scientists have studied the possibility of using engineered human adenoviruses as vaccines against diseases such as HIV, tuberculosis, and malaria. In this approach, adenoviruses, which commonly cause respiratory-tract infections, are rendered relatively harmless before they are used as vectors to deliver genes from pathogens, which in turn stimulate the body to generate a protective immune response.

In a new study of four adenovirus vectors, researchers from The Wistar Institute show that a reportedly rare human adenovirus, called AdHu26, is not so rare, after all, and would thus be unlikely to be optimal as a vaccine carrier for mass vaccination. As previous research has shown, a viral vector may be ineffective if the virus it is based on is common in a given population. According to the Wistar scientists, their study also supports the use of chimpanzee adenoviruses as vaccine vectors, since humans have little exposure to these viruses. Their findings were published online, ahead of print, in the Journal of Virology.

"Despite previous reports to the contrary, we find that AdHu26 commonly infects people, particularly those in Sub-Saharan Africa, the very people for whom the need for novel vaccine strategies is most dire," said senior author Hildegund C. J. Ertl, M.D., Wistar professor and director of The Wistar Institute's Vaccine Center. "HIV, malaria, and other infectious diseases take a tremendous toll in the developing world, especially in Sub-Saharan Africa, and a vaccine platform that could be used in those regions could save the lives of millions."

Scientists believe that prior immunity to human adenoviruses is what led, in part, to the failure in 2007 of the STEP trial, a large vaccine trial in the US and other countries that used an adenovirus vector as the basis for an HIV vaccine.

In the current study, Ertl and her colleagues analyzed blood samples collected from people at seven sites around the world, including Thailand, the United States, and five sub-Saharan African nations. They tested the samples to see if they contained neutralizing antibodies and responsive immune cells when exposed to AdHu26 and AdHu5, the virus used in the STEP trial. Surprisingly, neutralizing antibodies to AdHu26 were very prevalent in blood.

According to Ertl, adenoviruses are still good vaccine vectors, just not necessarily human adenoviruses.

In addition to testing AdHu5 and AdHu26, the Wistar scientists also tested two adenoviruses that originated in chimpanzees, called AdC6 and AdC7. As expected, neutralizing antibodies were far less likely to be detected in human samples. Mouse studies of all four vectors demonstrated that that were similar in their ability to generate cellular immune responses.

"This study also confirms our current line of research that suggests engineered chimpanzee adenovirus vectors could be superior to related, native human adenoviruses," Ertl said. "Both human and chimpanzee adenoviruses function in similar ways, but the simple benefit is that humans are rarely exposed to adenoviruses of chimpanzee origin."

The Ertl laboratory is currently developing an HIV vaccine utilizing chimpanzee adenoviruses.


'/>"/>

Contact: Greg Lester
glester@wistar.org
215-898-3943
The Wistar Institute
Source:Eurekalert

Related medicine news :

1. Marker of Ewing sarcoma: Potential new drug target?
2. New Website Provides Counselors with Instant Help for Troubled Kids
3. A New Website Series Improves Appearance and Health City by City
4. New York Truck Driver Watching Porn Kills Mother, Appalls Personal Injury Lawyers Such As David Perecman
5. New Report: The Internet Has More Influence Over Consumer Health Actions than Traditional DTC Channels
6. Top New York Dentists at Smile in the City Launch New Web Site
7. Medical Transcription Services and EHR Provider MxSecure Launches New Enhanced Website with Goal of Improved Physician Productivity
8. TV drama can be more persuasive than news program, study finds
9. Researchers discover new way to kill pediatric brain tumors
10. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
11. PHNS Implements New Accelerated Claims Resolution Services With iSoftStone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: